U.S. Tech Hardware Stock News

Investors may be wondering if Box is starting to look like a value opportunity after a rough patch, or if the market is rightly cautious about the stock at around US$22.82. The share price has been under pressure, with a 0.6% move over the last week, a 13.8% decline over 30 days, a 20.8% decline year to date, and a 31.1% decline over the past year. However, the 5 year return sits at 21.7%. Recent coverage around Box has focused on its position as a listed software player and how investors...

In February 2026, Gentherm reported fourth‑quarter 2025 earnings showing net income falling to US$2.99 million from US$15.32 million a year earlier, while quarterly revenue of about US$382.79 million came in ahead of expectations. Alongside weaker profitability, Gentherm issued product revenue guidance of US$1.5 billion to US$1.6 billion for 2026 and US$1.7 billion for 2027, highlighting its ambition to grow beyond automotive into medical and other precision thermal applications. We’ll now...

DigitalOcean Holdings FY 2025 Earnings Snapshot DigitalOcean Holdings (DOCN) has wrapped up FY 2025 with Q4 revenue of US$242.4 million and basic EPS of US$0.28, capping off a year in which trailing twelve month revenue reached US$901.4 million and EPS came in at US$2.83. The company has seen revenue move from US$780.6 million to US$901.4 million on a trailing twelve month basis, while EPS shifted from US$0.92 to US$2.83, with reported earnings growth helped by a very large year over year...

If you are wondering whether Bruker is priced attractively right now, you are not alone, especially with sentiment around the stock shifting recently. The share price closed at US$39.77, with a 4.3% gain over the last 7 days, set against returns of a 21.0% decline over 30 days, a 17.3% decline year to date, and a 21.6% decline over 1 year, as well as 41.7% and 35.1% declines over 3 and 5 years respectively. These mixed shorter term and longer term returns have put more attention on what...

If you are wondering whether TG Therapeutics at around US$30.51 is priced attractively or already baking in a lot of optimism, you are in the right place. The stock has returned 5.0% over the last 7 days, is down 2.2% over 30 days, and shows mixed longer term results with a 4.2% return year to date, 4.5% over 1 year, 90.4% over 3 years, and a 32.0% decline over 5 years. These moves sit against a backdrop of ongoing interest in TG Therapeutics as a biotechnology name, with investors watching...

Twist Bioscience, NasdaqGS:TWST, has entered a co exclusive licensing agreement with Invenra Inc. for Invenra's B Body bispecific antibody platform. The deal expands Twist's antibody discovery services and includes an equity investment and licensing terms that share economics between the two companies. This move adds bispecific antibody capabilities to Twist's existing biologics discovery tools, broadening the range of programs it can support for biotech and pharma customers. Twist...

If you are trying to work out whether Caris Life Sciences at around US$18.20 is a bargain or a value trap, you are in the right place. The stock has been under pressure recently, with a 12.5% decline over the last 7 days, a 27.2% decline over the last 30 days, and a 32.5% decline year to date. Recent attention around Caris Life Sciences has focused on its position in the pharmaceuticals and biotech space and how investors are reassessing risk in the sector. This backdrop helps explain why...

If you are wondering whether Danaos is still good value after its recent run, you are in the right place. This article focuses squarely on what you are paying for each dollar of the business. The stock last closed at US$111.57, with returns of 4.0% over 7 days, 10.8% over 30 days, 17.1% year to date, 41.5% over 1 year and 116.4% over 3 years. These figures naturally raise questions about how much upside or risk is now priced in. Recent coverage of Danaos has highlighted its role in the...

If you are wondering whether Inspire Medical Systems' share price now reflects good value or lingering risk, you are not alone. The stock last closed at US$57.72, with returns of 4.4% decline over 7 days, 27.3% decline over 30 days, 37.4% decline year to date, 68.8% decline over 1 year, 77.8% decline over 3 years and 76.1% decline over 5 years. Recent coverage has focused on how the share price pullback has reshaped expectations around the company and the sleep apnea treatment market it...

Concentra Group Holdings Parent: Recent Moves In Context With no single headline event driving attention to Concentra Group Holdings Parent (CON), investors are focusing on how its recent share performance and financial profile fit into the occupational health services story. See our latest analysis for Concentra Group Holdings Parent. At a share price of $23.41, Concentra Group Holdings Parent has paired a 1 month share price return of 8.63% with a year to date share price return of 20.61%...

In February 2026, Neurocrine Biosciences reported that fourth-quarter 2025 revenue rose to US$805.5 million and net income to US$153.7 million, with full-year revenue reaching US$2.86 billion and net income US$478.6 million, alongside higher basic and diluted earnings per share from continuing operations versus 2024. The company also issued 2026 guidance calling for INGREZZA net product sales of US$2.70 billion to US$2.80 billion, underscoring the central role of this flagship therapy in...

If you are wondering whether Regal Rexnord’s current share price really reflects what the business is worth, you are not alone. This article is built to help you assess that question clearly. With the stock at US$223.69 and returns of 2.1% over 7 days, 43.3% over 30 days, 53.1% year to date and 69.7% over 1 year, many investors are asking what is already priced in and what might still be on the table in terms of risk and reward. These moves sit against a backdrop where Regal Rexnord...

If you are wondering whether Knowles is fairly priced at around US$28.07 per share, you are not alone. This article will focus squarely on what that means for value minded investors. The stock has posted returns of 3.4% over the past week, 17.3% over the last 30 days, 27.9% year to date, 62.5% over 1 year and 65.3% over 3 years, with a 5 year return of 32.8%. This naturally raises questions about what is already reflected in the price. Recent coverage around Knowles has centered on its...

What the latest earnings and guidance mean for 10x Genomics (TXG) 10x Genomics (TXG) just paired its fourth quarter and full year 2025 results with new 2026 revenue guidance. This gives investors fresh data on growth, profitability and how management is framing the year ahead. See our latest analysis for 10x Genomics. 10x Genomics shares are at US$19.10, with a 1 day share price return of 1.11% and a 7 day share price return of 2.58%. The 30 day share price return shows a 14.66% decline,...

If you are wondering whether Dominion Energy's current share price offers real value or only appears reassuring at first glance, this article will help you make sense of where it stands. The stock last closed at US$63.74, with a 2.9% pullback over the past week, a 6.9% gain over 30 days, and returns of 7.6% year to date, 16.3% over 1 year, 33.1% over 3 years and 13.8% over 5 years. Recent coverage of Dominion Energy has focused on its position as a large regulated utility and on how...

Knife River (KNF) just reported fourth quarter and full year 2025 results, with revenue and net income above the prior year’s quarter, and issued 2026 revenue guidance in the US$3.3b to US$3.5b range. See our latest analysis for Knife River. The latest earnings and 2026 guidance arrived after a strong recent run in the share price, with a 30 day share price return of 21.07% and a 90 day share price return of 20.14%, even though the 1 year total shareholder return is a 4.59% decline, which...

Tanger (SKT) drew fresh attention after reporting fourth quarter and full year 2025 results, with higher sales, net income, and earnings per share, along with new 2026 earnings guidance and an update on its share repurchase activity. See our latest analysis for Tanger. At a share price of US$35.56, Tanger has seen a 30 day share price return of 9.25% and a 7.40% share price return year to date. Its 5 year total shareholder return of 169.79% points to strong longer term compounding, suggesting...

Analysts are flagging anticipated revenue declines for Fortive, citing softer demand and slower organic growth expectations. This shift in sentiment follows previously solid quarterly results and points to a possible inflection in the company’s operational outlook. The change comes as investors reassess Fortive’s near term growth profile beyond recent share price moves. For investors watching Fortive, ticker NYSE:FTV, the backdrop is a mix of steady share performance and growing questions...

Array Digital Infrastructure (NYSE:AD) has completed a transformation by selling its wireless operations and related spectrum assets. The company transferred spectrum holdings to major carriers, including T-Mobile and AT&T, and repositioned itself as a focused tower operator. Array Digital Infrastructure secured new long term Master License Agreements with top telecom companies for tower usage. The company distributed special dividends and outlined plans to invest further in its...

SI-BONE (SIBN) has wrapped up FY 2025 with Q4 revenue of about US$56.4 million and a basic EPS loss of US$0.04, alongside a trailing twelve month revenue base of roughly US$200.9 million and a TTM EPS loss of US$0.44. Over the past six quarters, revenue has moved from US$40.3 million in Q3 2024 to US$56.4 million in Q4 2025. Over the same period, quarterly basic EPS has ranged from a loss of US$0.16 in Q3 2024 to a loss of US$0.04 in the latest quarter, presenting a picture of expanding scale...

If you are wondering whether Tandem Diabetes Care at around US$26.90 is starting to look mispriced, you are not alone. The numbers give us plenty to unpack. The stock has seen sharp recent moves, with a 42.8% return over the last 7 days and 35.2% over the last 30 days. This is even though the 1 year return sits at a 19.3% decline and the 5 year return at a 71.2% decline. Recent news coverage has focused on Tandem Diabetes Care's position in diabetes technology and product updates that keep...

Dillard's (DDS) closed out FY 2026 with fourth quarter revenue of US$1,989.4 million and basic EPS of US$13.06, alongside net income of US$203.7 million. Earlier quarters showed revenue between US$1,490.97 million and US$1,546.97 million and EPS ranging from US$4.66 to US$10.39. Over the past year, the company reported trailing twelve month revenue of US$6.6 billion with basic EPS of US$36.32 and net income of US$570.2 million. These figures may prompt investors to focus closely on how...

Constellation Energy (CEG) has wrapped up FY 2025 with Q4 revenue of US$6.1b, Basic EPS of US$1.38 and net income of US$432m, putting a concrete set of numbers behind the recent share price of US$312.64. The company has seen quarterly revenue range between US$6.1b and US$6.8b across FY 2025, while Basic EPS moved from US$0.38 in Q1 to US$2.97 in Q3 before landing at US$1.38 in Q4, giving investors a clear view of how profit per share has shifted through the year. With trailing 12 month net...

Bank of Hawaii (NYSE:BOH) has announced that its CEO plans to retire at the end of March 2026. A board member recently executed a substantial sale of Bank of Hawaii shares. These leadership and ownership changes come as the stock last closed at $76.83. For investors watching Bank of Hawaii, the combination of a planned CEO retirement and a large board member share sale puts the focus squarely on governance and continuity. NYSE:BOH last closed at $76.83, with the stock showing returns of...